June 22, 2026 -- NanoGhost Ltd., a biotechnology company developing a proprietary targeted drug delivery platform for cancer and other severe diseases, announced today that it has been awarded a new grant from the Israel Innovation Authority to support an innovative collaborative research program with Ben-Gurion University of the Negev via its technology transfer company, BGN. This marks the sixth grant awarded to NanoGhost by the Israel Innovation Authority, reflecting continued confidence in

New funding will power foundational primary cell data generation to advance AI-driven discovery through the company's full product launch. June 22, 2026 -- DropGenie, a biotechnology company advancing next-generation gene editing workflows, today announced the closing of its Seed+ financing to support the launch of its first product. The round was led by Skeleton Key, with new investors Merck Global Health Innovation Fund and CQDM, and existing investors Real Ventures and Anges Québec continuin

Lead program, MMT-205, licensed from MabTics Co., Ltd / Curacle Co., Ltd. is a potential best-in-class bispecific antibody which activates Tie2 and inhibits VEGF, in development for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) In connection with the transaction, Memento Medicines has closed a $93M Series A financing, co-led by Forbion, RA Capital Management and Avego BioScience Capital, to support the progress of MMT-205 through IND-enabling and clinical

Memento’s lead asset is a bispecific antibody that blocks VEGF and activates Tie2. The biotech plans to test the candidate in retinal conditions such as neovascular age-related macular degeneration and diabetic macular edema. Memento Medicines has bagged $93 million in series A proceeds, which the Boston biotech plans to funnel toward a newly licensed asset for retinal disorders. In conjunction with the funding round, Memento struck up an exclusive deal with MabTics and Curacle, paying unspecif

Nura Bio, a neuroscience-focused biotech with a novel approach to treat disorders like amyotrophic lateral sclerosis (ALS), pulled in $73.8 million in a series B funding round to support two clinical programs that could potentially address neurological conditions with high unmet need. ALS, in particular, has been a daunting challenge for drugmakers. Only a select few, including Biogen’s Qalsody, have broken through to the market, leaving patients with limited options to treat a devastating and

June 13, 2026 -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma ecosystem with Europe, today announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123M (€106M). Following its initial launch in December 2025, the fund has secured backing from a syndicate of prominent institutional investors—including lead investor Hellenic Development Bank of Investments (HDBI)—and global family offices.

Financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors Proceeds will support clinical advancement of lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closin

– ETHY-001 targets the causal pathogenic mechanism underlying both conditions – – Patient-friendly subcutaneous administration with half-life extension for infrequent dosing – – First-in-human clinical trial expected to initiate in the second half of 2026 – – Preclinical data to be presented in an oral presentation at ENDO on June 15, 2026 – – Backed by leading healthcare investors including Atlas Venture, Medicxi Ventures, Avoro Capital, Nandi Life Sciences, and Checkpoint Capital – June 10, 2

Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, today announced the closing of a $6 million financing round led by VCapital, with participation from Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis. In addition to the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program in animal health. T

Roche is wagering billions of dollars on a medicine that trashes a troublesome protein instead of stifling its activity. The Swiss drugmaker on Monday reached a deal with Nurix Therapeutics to codevelop a therapy called bexobrutideg that’s nearing late-stage testing. Roche will pay Nurix $700 million up front and, in return, will split U.S. rights to the drug while gaining full ownership elsewhere. Roche will also cover 60% of the development costs and hand Nurix royalties on non-U.S. sales. N